Objectives: Since treatment regimen type can influence adherence and other outcomes, this study examined adherence, cardiovascular events, and economic outcomes in patients with hypertension treated with fixed-dose combination (FDC) amlodipine/olmesartan (AML/ OM), FDC AML/benazepril (AML/BEN), and loose-dose combination AML plus angiotensin II receptor blockers (LDC AML/ARBs). Methods: Commercial health plan enrolees aged at least 18 years with index claim(s) for AML/OM, AML/BEN, or LDC AML/ARB were identified. Absence of study drug 6 months pre index, and continuous enrolment for at least 12 months post index were required. Descriptive analyses were executed to make comparisons between treatments, as well as multivariate models adjusting for baseline demographic and clinical characteristics, including propensity for assignment to study drug. Results: Descriptive results suggested mean follow-up adherence was higher in the AML/OM cohort [proportion of days covered (PDC) = 0.63] compared with the AML/BEN (PDC = 0.55; p < 0.001) and LDC AML/ARB cohorts (PDC = 0.34; p < 0.001). The proportion of individuals with an incident follow-up cardiovascular event composite was lower in the AML/OM cohort versus the AML/BEN and LDC AML/ARB cohorts (5.94% versus 7.85% and 16.89% respectively). Adjusted Cox models suggested that patients initiated on LDC AML/ARB (hazard ratio 1.35; p < 0.001), but not on AML/BEN, were at greater risk of a follow-up cardiovascular event (composite) compared with AML/OM. Adjusted generalized linear models suggested that mean follow-up per-member-per-month overall costs were higher in the AML/BEN (cost ratio = 1.169; p < 0.001; unadjusted mean cost US$780) and LDC AML/ARB cohorts (cost ratio = 1.286; p < 0.001; unadjusted mean cost US$1394) compared with the AML/OM cohort (unadjusted mean cost US$740).
Introduction
Essential hypertension is a major public health concern affecting nearly 76.4 million people in the United States alone [Roger et al. 2012] ; the prevalence of hypertension is expected to increase by an additional 27 million people worldwide by the year 2030 [Heidenreich et al. 2011] . Uncontrolled hypertension can lead to stroke, cardiac failure, end-stage renal disease, and death [Psaty et al. 2001] . Although awareness and control of hypertension has increased over the last three decades, hypertension remains inadequately managed in approximately 50% of all patients [Egan et al. 2010] . Patients with uncontrolled hypertension can incur incremental costs compared with patients with adequately controlled blood pressure (BP) [Paramore et al. 2001; Flack et al. 2002] . In 2010, costs attributable to hypertension were estimated to be more than US$76 billion, with US$54.9 billion and US$21.7 billion in direct and indirect costs respectively [Lloyd-Jones et al. 2010] . Numerous treatment options are available to lower BP within goal levels recommended in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP (JNC 7) [Chobanian et al. 2003 ]. All antihypertensive agents in general, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), β blockers, calcium channel blockers (CCBs), and thiazide-type diuretics reduce complications of hypertension [Neal et al. 2000] ; however, the majority of patients require combination therapy to achieve targeted BP goals and reduction in cardiovascular (CV) risk [Black et al. 2001; Cushman et al. 2002] . Combining agents from diverse, yet complimentary, classes provides a mechanism to target the disease through multiple physiologic actions [Faulkner and Hilleman, 2001; Sica, 2002] . According to JNC 7 guidelines, BP in excess of 20/10 mmHg of goal should be initially treated with two drugs, separately or with fixed-dose combinations (FDCs). This recommendation is based on evidence that combination therapy increases the probability of achieving BP goals within a shorter time period compared with single-drug therapy [Chobanian et al. 2003] .
A CCB and ARB combination regimen is a rational choice based on their complementary mechanisms of action. Addition of an ARB to a CCB lends itself to improved tolerability, for example, CCBs stimulate arterial vasodilation to a greater extent than venodilation, thereby causing fluid accumulation in interstitial spaces, whereas ARBs increase both arterial and venous dilation and thus function to counteract some of the CCB-induced arterial dilation, which is thought to result in a corresponding reduction in lower-extremity edema [See, 2001; Sica, 2003 ]. Furthermore, while both CCBs and ARBs act synergistically to reduce vascular smooth muscle contractility [Oparil and Weber, 2009; Gradman et al. 2010] , FDCs are associated with improved treatment outcomes and greater adherence to therapy compared with loose-dose combinations (LDCs) [Gerbino and Shoheiber, 2007; Tejada et al. 2007] . The objective of the present study is to compare CV outcomes, adherence, switching, augmentation, healthcare resource utilization, and costs for patients with hypertension initiated on FDC amlodipine/olmesartan (AML/OM) with those of patients initiated on FDC AML/ benazepril (AML/BEN) or LDC AML plus ARBs (LDC AML/ARB). Single-agent ARB medications that could be used in LDC AML/ARB therapy included candesartan, eprosartan, irbesartan, losartan, OM, telmisartan, and valsartan.
Methods

Data source
A retrospective observational study was conducted using data from medical and pharmacy claims for the period from 1 March 2007 to 31 December 2009 within a large US managed care health plan affiliated with OptumInsight, Inc. (www.optuminsight.com). Member coverage is geographically diverse, with coverage across all US census regions. Since individual identities or medical records were not disclosed, and data were accessed using methods consistent with the Health Insurance Portability and Accountability Act [United States, 1996] , institutional review board approval was not required for this study.
Patient identification
The process involved in selecting the study sample is outlined in Figure 1 . The study included commercial health plan enrolees aged 18 years and older, who initiated FDC AML/OM, FDC AML/BEN, or LDC AML plus ARBs between 1 September 2007 and 31 December 2008. The index date was the date of first pharmacy claim for the FDC cohorts or the date of the first claim for the second of the two medications constituting the LDC cohort. Patients required at least one pharmacy claim for FDC AML/OM or FDC AML/BEN during the identification period. LDC AML plus ARBs treatment episode was defined as a set of two pharmacy claims; a single-pill pharmacy claim for an ARB on the same date as, or followed by, a single-pill pharmacy claim for AML or vice versa. The date of the pharmacy claim for single-agent ARB must have been within 30 days of the date of the pharmacy claim for AML. Additionally, the fill for the second claim must have occurred prior to the run out of the first (i.e. the days' supply for the two active ingredients must have 'overlapped').
Patients with medical and pharmacy benefits who were continuously enrolled in the plan for a minimum of 6 months prior to the index date (baseline period) and at least 12 months following the index date (follow-up period) were included. Patients were required to have a primary or secondary diagnosis code for hypertension during the baseline period [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes: essential hypertension, 401.x; hypertensive heart disease, 402.xx; hypertensive chronic kidney disease, 403.xx; hypertensive heart and chronic kidney disease, 404.xx]. Patients were excluded if they had any pharmacy claims for FDC AML/OM, FDC AML/BEN, or LDC AML plus ARBs during the baseline period. Patients with any ICD-9-CM diagnosis, ICD-9-CM procedure, or Healthcare Common Procedure Coding System (HCPCS) codes for pregnancy, labor, or delivery during the study period were also excluded.
Study measures
Outcome measures. All outcomes were measured in the follow-up period, inclusive of the index date. Follow-up duration was calculated for each patient as number of days from the index date to the end of the follow-up period. Adherence to the prescribed regimen and persistence with therapy were measured using follow-up claims for the index medication inclusive of pharmacy claims on the index date. Adherence with index therapy was measured as the proportion of days covered (PDC). PDC was defined as the total number of days of therapy with the index medication during the follow-up period divided by the number of follow-up days. For the LDC AML plus ARBs cohort, days on index therapy were calculated using the methodology of Leslie and colleagues [Leslie et al. 2008] , with days on index therapy equal to the days in which patients had access to both agents. PDC values were categorized as at least 0.80, which suggested good adherence, and less than 0.80, which suggested suboptimal adherence. Persistence with therapy was measured as days from the index date to therapy discontinuation date (first gap in therapy of 60 days or greater). Index therapy augmentation was assessed as a pharmacy claim for an antihypertensive medication in a class other than that of the index drug (or for an antihypertensive medication in the same class as the index drug, but with a different molecular makeup) during the follow-up period, more than 60 days prior to discontinuation of index therapy. There must have been at least one more continuous fill for the index drug after the first fill for the augmented drug. Index therapy switch was identified for patients who discontinued their index regimen. The pharmacy claim for a new antihypertensive medication other than index must have occurred within 60 days prior to the end of the index therapy through 90 days following the end of the index therapy.
The primary clinical outcome assessed was a composite measure of the first observed clinically significant CV event in the follow up, identified using diagnosis (primary or secondary) or procedure codes on medical claims. Clinically significant CV events included heart failure (ICD-9-CM diagnosis codes: 428. 0, 428.1, 428.21, 428.23, 428.31, 428.33, 428.41, 428.43, 428.20, 428.30, and 428.40; or 428.20, 428.30, 428.40, and 428.9 if none of these four codes occurred in the prior 60 days); stroke (ICD-9-CM diagnosis codes, during inpatient (hospital) stay: 430, 431, 432.x, 433.x1, 434.x1, 436) ; myocardial infarction (MI; ICD-9-CM diagnosis code, during inpatient stay: 410.xx); acute ischemic heart disease (IHD) diagnosis (other than MI; ICD-9-CM diagnosis codes, during inpatient stay: 411.1, 411.8x); or surgery related to MI/IHD (including percutaneous coronary intervention; HCPCS codes: 33510-33523, 33533-33536, 33572, 92980-92981, 92982-92984, 92995-92996, 92973 , G0290-G0291, S2205-S2209; ICD-9-CM procedure codes: 00.66, 36. 01-36.02, 36.03, 36.05, 36.06, 36.07, 36.09, 36.1x) .
Economic outcomes were assessed as permember-per-month (PMPM) healthcare resource utilization and PMPM healthcare costs (all cause and hypertension attributable). Hypertensionattributable medical resource utilization and costs were defined based on claims associated with ICD-9-CM diagnosis, ICD-9-CM procedure, HCPCS, and revenue codes for hypertension; while hypertension-attributable pharmacy resource utilization and costs were defined based on pharmacy claims for antihypertensive medications. Healthcare resource utilization included ambulatory visits (office and outpatient), emergency department (ED) visits, inpatient stays, inpatient days, and pharmacy claims. Healthcare costs were computed as the combined health plan-and patient-paid costs in the follow-up period and included medical and pharmacy costs. Patient characteristics. Patient demographic characteristics, including age, sex, insurance type, and geographic region were captured. Baseline comorbidities were recorded using ICD-9-CM diagnosis, ICD-9-CM procedure, HCPCS, and revenue codes, and pharmacy claims, and included depression, diabetes, hypercholesterolemia or hypertriglyceridemia, heart failure, stroke or transient ischemic attack (TIA), MI, IHD (other than MI), peripheral vascular disease, left ventricular hypertrophy (cardiomegaly), cerebrovascular disease other than stroke or TIA, chronic kidney disease, and other kidney disease. Additionally, ICD-9-CM diagnosis codes were used to identify baseline comorbid conditions as defined by Quan and colleagues [Quan et al. 2005] , which were used to score the Quan-Charlson comorbidity index [Charlson et al. 1987] . Baseline PMPM all-cause healthcare resource utilization and healthcare costs were also captured as described for follow-up economic outcomes.
Statistical analysis
Descriptive and multivariate approaches were executed for two sets of cohort comparisons: FDC AML/OM cohort versus FDC AML/BEN cohort, and FDC AML/OM cohort versus LDC AML plus ARBs cohort. All study variables, including baseline and outcome measures, were analyzed descriptively. χ 2 tests were used to examine cohort differences in categorical baseline characteristics (e.g. patient demographic and clinical characteristics) and in the distributions of follow-up clinically significant CV events. The independent samples (two-sided) t test was used to evaluate cohort differences in continuous variables (e.g. mean age, Quan-Charlson comorbidity score, baseline and follow-up economic characteristics, and length of follow up).
The associations between treatment cohort and follow-up therapy PDC at least 0.80, follow-up CV event, PMPM healthcare resource utilization, and PMPM healthcare costs were analyzed with multivariate regression models, adjusting for covariates. Follow-up therapy PDC at least 0.80 was analyzed using logistic regression; time to first follow-up CV event was analyzed using Cox proportional hazards models; follow-up healthcare resource utilization outcomes were analyzed using negative binomial regression; and follow-up healthcare costs were analyzed using generalized linear models with a γ distribution and log-link function. The γ distribution and log-link account for the skewed distribution of costs.
All analyses were adjusted for baseline demographic and clinical characteristics that included age, sex, geographic region, and number of baseline nonindex hypertension medication classes (i.e. ARBs, diuretics, ACEIs, CCBs, β blockers, ACEI/CCB, ARB/CCB, and other antihypertensives). Models were further adjusted in the following ways: event models were adjusted for baseline all-cause healthcare resource utilization and baseline comorbidities (defined above); resource utilization and PDC at least 0.80 models were adjusted for baseline all-cause healthcare resource utilization, baseline Quan-Charlson comorbidity score, and select baseline comorbidities not overlapping with the Quan comorbidity algorithms (i.e. depression, hypercholesterolemia or hypertriglyceridemia, IHD other than MI, and nonchronic kidney disease); and cost models were adjusted for log-transformed baseline all-cause medical costs and pharmacy costs, baseline Quan-Charlson comorbidity score, and select baseline comorbidities not overlapping with the Quan comorbidity algorithms.
Multivariate analyses were further adjusted using propensity score subclassification. Propensity estimates for treatment cohort (for each of the two sets of cohort comparisons) were generated using logistic regression models, adjusting for age, gender, region, baseline comorbidities, baseline all-cause healthcare resource utilization, and baseline nonindex hypertension medication classes. Cox proportional hazards model estimates were also generated for each propensity score quintile (PSQ) to provide additional granularity to the comparisons between cohorts.
Estimated hazard ratios (HRs), odds ratios (ORs), incidence rate ratios and cost ratios were computed [along with standard errors, associated two-tailed p values and 95% confidence intervals (CIs)] to test the association between independent variables and follow-up outcomes (CV events, PDC ≥0.80, healthcare resource utilization and costs respectively).
Results
Patient characteristics
A total of 24,663 patients were identified for inclusion in the study; baseline demographic and clinical characteristics by cohorts are presented in Table 1 . The FDC AML/BEN cohort was most populous (48.9%; n = 12,051), followed by the LDC AML plus ARBs (31.4%; n = 7748) and FDC AML/OM (19.7%; n = 4864). Patients in the FDC AML/OM cohort were younger. Larger proportions of patients in the FDC cohorts were men and located in the South. Patients in the FDC AML/OM cohort largely had a similar comorbidity profile at baseline compared with the FDC AML/BEN cohort; however, the prevalence of comorbidities in the LDC cohort at baseline was greater (Table 1) . Further, the mean baseline Quan-Charlson comorbidity score in the FDC AML/OM cohort was 0.72, which was lower than the LDC AML plus ARBs cohort (1.48; p < 0.001). Use of antihypertensive medications during the baseline period was consistently higher in the LDC AML plus ARBs cohort compared with the FDC AML/OM cohort. Select baseline PMPM all-cause healthcare resource utilization and healthcare costs differed by cohorts; the mean PMPM all-cause medical costs at baseline in the FDC AML/OM cohort was lower compared with the FDC AML/BEN and LDC AML plus ARBs cohorts (US$516, US$590, and US$1302 respectively).
Follow-up index therapy utilization and adherence patterns
The mean duration for follow up was 543 days, 585 days, and 625 days for the FDC AML/OM, LDC AML plus ARBs, and FDC AML/BEN cohorts respectively (p < 0.001; Table 2 ). Mean time to switch and mean time to augmentation were lower (p < 0.001 for both) in the FDC AML/ OM cohort compared with the LDC AML plus ARBs cohort respectively.
A greater proportion of patients (44.12%) in the FDC AML/OM cohort achieved good adherence (PDC ≥0.80) to index therapy compared with those in the FDC AML/BEN (36.46%; p < 0.001) and LDC AML plus ARBs (19.53%; p < 0.001) cohorts. Multivariate logistic regression analysis results modeling PDC at least 0.80 suggested that, compared with patients in the FDC AML/ OM cohort, those in the FDC AML/BEN (OR 0.76; p = 0.002) and LDC AML plus ARBs (OR −0.24; p < 0.001) cohorts were less likely to be adherent to the index regimen. Furthermore, mean persistence was lower in the LDC AML plus ARBs cohort compared with the FDC AML/ OM cohort (p < 0.001); however, there was no statistically significant difference when the FDC AML/BEN cohort was compared with the FDC AML/OM cohort (p = 0.210).
Follow-up clinical outcomes
The proportion of patients who experienced an incident composite CV event in the follow up was lower in the FDC AML/OM cohort versus FDC AML/BEN and LDC AML plus ARBs cohorts (5.94% versus 7.85% and 16.89% respectively) ( Table 3 ). Similar differences existed among the cohorts in terms of the individual components of the CV event composite (i.e. heart failure, stroke, MI, acute IHD diagnosis, and MI/IHD-related surgery). Multivariate adjusted Cox models suggested that, compared with FDC AML/OM, patients initiated on LDC AML plus ARBs were at greater risk (p < 0.001) of an incident CV event composite. There was no statistical difference in the risk of an incident CV event composite between FDC AML/OM and FDC AML/BEN (p = 0.085). Compared with subjects in the FDC AML/OM cohort, the Cox models calculated a higher adjusted risk for subjects in the LDC AML plus ARBs cohort for heart failure (p = 0.005), stroke (p = 0.007), and MI/IHD-related surgery (p = 0.042), but not for MI (p = 0.313) or acute IHD diagnosis (p = 0.065). The adjusted estimated risk of stroke was higher for patients in the FDC AML/BEN cohort (p = 0.038) compared with the AML/OM cohort.
Additional analyses examined the association between treatment cohort and the composite CV event within each PSQ. Table 4 presents the baseline Quan-Charlson comorbidity score by PSQ, as well as the results from the Cox proportional hazards regression model comparing risk of composite CV events between treatments in each PSQ. For the comparison between FDC AML/OM and AML/BEN, there were no differences between comparators within any of the PSQ. For the comparison between FDC AML/ OM and LDC AML plus ARBs, there was a greater risk of a composite CV event in the LDC cohort in quintiles 1, 2, and 3. For this comparison, PSQ 1 represented patients with the fewest baseline comorbidities while PSQ 5 was reflective of patients who had the most comorbidities at baseline.
Follow-up healthcare resource utilization and costs
Follow-up healthcare resource utilization and costs are reported in Table 5 . Both descriptive and multivariate analysis results are shown for each treatment cohort. Results from the negative binominal regression models, controlling for baseline demographics and clinical characteristics, indicated that the rate of follow-up all-cause ambulatory visits was higher in the FDC AML/ BEN (p < 0.001) and LDC AML plus ARBs (p < 0.001) cohorts compared with the FDC AML/ OM cohort (Table 5) . Similar results were observed in the case of hypertension-attributable ambulatory visits. Utilization of all-cause ED visits was higher for the FDC AML/BEN cohort versus the FDC AML/OM cohort (p < 0.006), but not different versus the LDC AML plus ARBs cohort. However, utilization of hypertensionattributable ED visits was higher in the LDC AML plus ARBs cohort (p < 0.001) and the FDC AML/BEN cohort (p < 0.002) compared with the FDC AML/OM cohort. The rates of both allcause and hypertension-attributable inpatient stays were higher in the FDC AML/BEN (allcause: p < 0.001; hypertension attributable: p < 0.001) and LDC AML plus ARBs (all cause: p < 0.001; hypertension attributable: p < 0.001) cohorts compared with the FDC AML/OM cohort. In comparison with the AML/OM cohort, the utilization of all-cause and hypertensionattributable inpatient days was also greater in the AML/BEN and LDC AML plus ARBs cohorts. The rates of both all-cause and hypertensionattributable pharmacy utilization were higher in the FDC AML/BEN (all cause: p < 0.001; hypertension attributable: p < 0.001) and LDC AML plus ARBs (all cause: p < 0.001; hypertension attributable p < 0.001) cohorts compared with the FDC AML/OM cohort.
Mean follow-up PMPM all-cause overall, medical, and inpatient costs were lower in FDC AML/ OM cohort (US$740, US$502, and US$142, respectively) compared with the FDC AML/BEN (US$780, US$575, and US$199, respectively) and LDC AML plus ARBs cohorts (US$1,394, US$1,049, and US$366, respectively). A similar trend in costs was observed for hypertensionattributable costs. Adjusted results from generalized linear regression analyses suggest higher adjusted follow-up PMPM overall healthcare costs in the FDC AML/BEN (all cause: p < 0.001; hypertension attributable: p < 0.001) and LDC AML plus ARBs cohorts (all cause: p < 0.001; hypertension attributable: p < 0.001). Compared with the FDC AML/OM cohort, medical costs were higher in the FDC AML/BEN cohort (all cause: p < 0.001; hypertension attributable: p < 0.001) and LDC AML/ARB cohorts (all cause: p < 0.001; hypertension attributable: p < 0.001). Only in the case of hypertension-attributable pharmacy costs were costs lower in both the FDC AML/BEN (p < 0.001) and LDC AML plus ARBs (p < 0.001) cohorts compared with the FDC AML/OM cohort. Compared with the FDC AML/OM cohort, inpatient costs were higher in the FDC AML/BEN (all cause: p < 0.001; hypertension attributable: p < 0.001) and LDC AML plus ARBs cohorts (all cause: p < 0.001; hypertension attributable: p < 0.001). 
Discussion
To the best of our knowledge, this is the first study that addressed questions with respect to the realworld outcomes associated with combination therapy in the management of hypertension by examining the association between the use of combination (FDC and LDC) AML with reninangiotensin system inhibitor therapies and clinical outcomes, a critical gap in the medical literature. Further, the magnitude of the clinical outcome difference between these therapies was estimated in terms of healthcare resource utilization and cost. Lastly, the differential impact on clinical and economic outcomes was also evaluated for AML-based FDCs that include OM or an ACE inhibitor, specifically, BEN. The study also showed an apparent superiority of the FDC of AML/OLM versus the FDC of AML/BEN in terms of CV events. The additional benefit of the combination of AML/OLM may be related to the higher specificity of angiotensin II blockade through direct blockade of angiotensin II receptors, although additional factors such as higher tolerability cannot be excluded.
Findings from this study showed that persistence and adherence with therapy was greater with FDC than with LDC therapy. Furthermore, persistence with FDC AML/OM was greater than with LDC AML plus ARBs. It was also observed that the risk of an incident CV event and utilization of healthcare resources was lowest in the FDC AML/OM cohort; at the same time, the highest mean adherence among the comparators was observed in the FDC AML/ OM cohort. These outcomes translated into lower all-cause and hypertension-attributable healthcare costs in the FDC AML/OM cohort relative to the FDC AML/BEN and LDC AML plus ARBs cohort.
The results of this study echo findings from previous studies comparing FDC and LDC regimens on adherence and persistence outcomes [Bangalore et al. 2007; Brixner et al. 2008; Hess et al. 2008; Gupta et al. 2010; Yang et al. 2010; Zeng et al. 2010] . Patients receiving FDC versus LDC regimens had 6.6% greater adherence (p < 0.001) in a nationally representative retrospective claims analysis [Brixner et al. 2008] and were more likely to be adherent (OR 2.915; p < 0.001) and less likely to discontinue therapy (HR 0.537; p < 0.001) in another analysis [Zeng et al. 2010] . Similarly, FDC therapy compared with LDC therapy was associated with a 26% lower risk of nonadherence (p < 0.0001) in one meta-analysis [Bangalore et al. 2007 ] and associated with 29% (95% CI 11%-50%) greater adherence and persistence in another meta-analysis [Gupta et al. 2010 ]. An association between improved therapy adherence and reduced risk of CV events has previously been established and past results are consistent with our current findings. In a recent retrospective cohort evaluation, increasing adherence to a once-daily antihypertensive regimen by one pill/ week reduced multivariate-adjusted mortality risk by 7% (HR 0.93; 95% CI 0.90−0.096) [Bailey et al. 2010] . Similarly, in separate evaluations, high adherence or persistence with antihypertensive therapy was shown to significantly reduce the risk of CV events by 38% (HR 0.62; 95% CI 0.40−0.96) [Mazzaglia et al. 2009 ] while nonadherent patients had 68% more ED visits (p < 0.0001) ].
Greater persistence with hypertensive therapy has been associated with lower healthcare resource use [Mccombs et al. 1994; Rizzo and Simons, 1997; Sokol et al. 2005 ] and hospitalization rates [Hess et al. 2008 ]. Pittman and colleagues found that regression-adjusted healthcare costs increased as adherence decreased [Pittman et al. 2010] ; mean costs for patients with a medication possession ratio (MPR) of 80% or higher (US$7182) were significantly lower than patients with an MPR ranging from 60% to 79% (US$7560) or for patients with an MPR less than 60% (US$7995) (p < 0.001 for both). The odds of CV-related hospitalizations (OR 1.33; 95% CI 1.25-1.41) and ED visits (OR 1.45; 95% CI 1.33-1.58) (p < 0.001) were significantly greater among patients with low or moderate adherence [Pittman et al. 2010] . Similar findings from the literature were compiled in a meta-analysis of 12 retrospective claims database studies which showed that the mean difference in combined total annual hypertension-related and all-cause healthcare costs was US$1357 lower in the single-pill FDC group compared with the LDC group [Sherrill et al. 2011] .
The findings from this study can have significant implications from the perspective of providers, payers, and patients. Often, providers lean towards LDCs given the flexibility to titrate dose for individual patients to the optimal level. This may inadvertently lead patients to not use all the prescribed agents as intended either due to regimen complexity, lack of understanding regarding the importance of taking all medications, or access to one component of the regimen, which may have higher co-pays [Bangalore and Ley, 2012] . These barriers to optimal adherence may be compounded by inadequate follow-up visits when there is maximal opportunity to influence patients. In many cases, the opportunity to achieve goal or good control with low doses of FDC therapy may have been lost: with FDC therapy, patients 'may achieve the goal of reaching target BP sooner as a first-line approach', with a regiment that may be cost effective as well as simple to take for the patient [Neutel, 2011: 88] .
From a payer perspective, plans with formulary restrictions such as prior authorizations, step-up therapy requirements, or higher co-pays for FDC therapies may not be factoring in the potential medical cost savings that may not only offset the incremental acquisition costs of FDCs, but also may result in cost savings through the efficient use of FDC antihypertensive therapy. From a patient perspective, 'use of true once-daily single-pill combination therapy with effective and well-tolerated agents can reduce pill burden, simplify treatment regimens and improve treatment adherence, which can, in turn, help patients to reach and maintain their blood pressure target and achieve the short-and long-term treatment goal of CV risk reduction' [Bangalore and Ley, 2012: 345] .
Administrative claims are a strong data asset that allow evidence-based examination of healthcare utilization and costs and typically provide robust sample sizes coupled with diverse patient makeups. Other studies have supported the evaluation of such claims for the same purpose [Christensen et al. 1994; Choo et al. 1999 ]. However, administrative claims have some limitations that should be considered in this retrospective study. Due to the observational nature of claims data, evidence of a pharmacy fill does not guarantee that a subject adhered to the regimen; however, claims data most often serve as a proxy for measuring adherence. Additionally, clinically significant CV events may result from a multitude of factors, and no causal link to treatment may be inferred from claims data. Another limitation of this study is the selection bias associated with subjects identified for inclusion in each cohort. The LDC AML plus ARBs cohort had a higher representation of older and sicker patients. Although propensity score subclassification techniques were implemented, residual confounding by selection bias cannot be ruled out. Given the over representation of patients from the 'South' region in the database, it is plausible that the cost data may not be uniform to the entire USA due to differential regional variations in payment and cost structures.
In summary, this study extends findings from the literature that good adherence rates on average are quite low, ranging between 20% and 45% among studied treatment groups, which further highlights the significance of nonadherence to treatment as a major public health issue. However, our data demonstrate that patients on FDCs were more adherent and persistent with therapy than patients on LDCs. Treatment with AML/OM was associated with greater adherence and persistence than treatment with AML/BEN and LDC AML plus ARBs. Greater adherence, lower healthcare resource utilization costs, and lower incidence of CV events over the follow up were observed concurrently. These data suggest that large improvements in patient outcomes and system-wide cost savings may be realized from relatively modest improvements in adherence. The economic impact of chronic care diseases on the US healthcare system continues to grow unabated. Among the various approaches that are needed to reduce healthcare costs, improved adherence to therapy is one factor that is known to decrease the burden of CV events. Additional large-scale studies on the use of FDCs in terms of clinical outcomes may be one effective approach to address these issues.
